[HTML][HTML] Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer Chemotherapy …, 2016 - Springer
Abstract Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-
ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of …
ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer …, 2016 - search.proquest.com
Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
[引用][C] Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer Chemotherapy …, 2016 - cir.nii.ac.jp
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a
randomized, placebo-controlled crossover study | CiNii Research CiNii 国立情報学研究所 学術 …
randomized, placebo-controlled crossover study | CiNii Research CiNii 国立情報学研究所 学術 …
[PDF][PDF] Effect of veliparib (ABT‑888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo‑controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer Chemother …, 2016 - cyberleninka.org
Accepted: 6 September 2016/Published online: 5 October 2016© The Author (s) 2016. This
article is published with open access at Springerlink. com bound (UCB) for the mean …
article is published with open access at Springerlink. com bound (UCB) for the mean …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
W Munasinghe, S Stodtmann, A Tolcher… - Cancer …, 2016 - europepmc.org
Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
[HTML][HTML] Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer …, 2016 - ncbi.nlm.nih.gov
Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer …, 2016 - research.rug.nl
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors:
a randomized, placebo-controlled Page 1 University of Groningen Effect of veliparib (ABT-888) …
a randomized, placebo-controlled Page 1 University of Groningen Effect of veliparib (ABT-888) …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann… - Cancer …, 2016 - cris.maastrichtuniversity.nl
Abstract Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann, A Tolcher… - Cancer Chemotherapy …, 2016 - infona.pl
Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
W Munasinghe, S Stodtmann… - Cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-ribose)
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …
polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on …